Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer
Menée à partir de données histologiques portant sur 213 patients atteints d'un cancer et présentant une hépatite de haut grade liée aux inhibiteurs de point de contrôle immunitaire, cette étude analyse l'utilité d'une biopsie hépatique pour diagnostiquer et traiter les lésions
The utility of liver biopsy in diagnosis and management of immune checkpoint inhibitor (ICI) hepatitis is uncertain.1-3 We examined the association of histology with management and outcomes of high-grade ICI hepatitis.
A total of 7046 patients with cancer (excluding hepatocellular carcinoma) received ICI treatment between January 2010 and June 2020. We performed a retrospective cohort study of the 213 patients who developed grade 3 or higher (alanine aminotransferase [ALT] level, >200 U/L [to convert to
μkat/L, multiply by 0.0167]) liver injury that was associated with ICI treatment. Approval for the study was obtained from the Mass General Brigham institutional review board, and informed consent was waived due to the retrospective nature of the study.
JAMA Oncology , résumé, 2020